Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    No significant changes to core study information (design, eligibility criteria, endpoints, or results) are evident between the screenshots; the differences appear limited to minor UI/formatting updates. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T01:18:14.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Core content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-05T10:34:19.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Update the page to a new revision: from v3.0.2 to v3.1.0.
    Difference
    0.1%
    Check dated 2025-09-28T03:22:14.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.
    Difference
    0.2%
    Check dated 2025-09-13T17:38:56.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T15:22:06.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility names and locations, as well as a revision to the content related to cancer topics and immunological agents. Notably, the previous version's references to certain cancer types and treatments have been removed.
    Difference
    6%
    Check dated 2025-08-30T12:04:43.000Z thumbnail image

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.